Plus   Neg

Stock Alert: Citius Pharmaceuticals Soars 50%

Shares of Citius Pharmaceuticals, Inc. (CTXR) are adding nearly 50% on Friday morning after the U.S. FDA told the company that it could apply for fast track designation for its Induced Mesenchymal Stem Cells to treat patients with COVID-19.

CTXR is currently trading at $1.61, up $0.53 or 49.07%, on the Nasdaq.

Citius Pharma announced it received a written response from the FDA in regards to its pre-investigational new drug application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control requirements for the proposed trials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
DMM Vission is recalling five lots of Cleaner Hand Sanitizer due to potential presence of methanol (wood alcohol), the U.S. Food & Drug Administration said in a statement. The company is yet to receive any reports of adverse events involving the product. Facebook Inc. said it will ban ads that seek to delegitimize the Presidential election. The announcement is in line with the social media giant's decision to prohibit ads that make premature declarations of victory as it aims to protect the integrity of the upcoming U.S. 2020 elections. Rob Leathern, Director of Product Management, in a tweet said that these changes apply to ads across Facebook... While reporting financial results for the first quarter of fiscal 2021 on Thursday, Conagra Brands, Inc. (CAG) provided only its adjusted earnings and organic net sales growth guidance for the second quarter of fiscal 2021. The company is still not initiating annual outlook, as is usual, as the impact...
Follow RTT